The 22nd Annual BIO CEO & Investor Conference assembles a select group of established biotech companies, as well as top public and private equity investors and members of the sell-side investment community, to explore the current investment landscape and opportunities in life sciences. In addition to plenary sessions and panel discussions on timely business topics and key therapeutic areas, the conference features presentations by over 175 leading biotechnology and pharmaceutical companies, as well as a number of nonprofit and venture philanthropy organizations.
Presenting companies are hand-selected for the event, and consist of a selection of mid- to large-cap established public companies from around the globe, who typically have a clinical stage program centered around therapeutics, molecular diagnostics, or a platform technology, as well as an upcoming clinical, regulatory, or corporate catalyst.
The typical audience for a company presentation features public and private equity investors, as well as industry analysts, investment bankers and senior biotechnology executives. All company presentations are 13 minutes in length, and are noted as such in the conference program and materials. All Q&A from the audience, should a company want to take questions, are included in those times.
A special track of presentations will feature private companies. Presentations in this track will be 13 minutes in length, and will be reserved specifically for established private companies (past Series B round and >$25M raised to date). Please note, registration fees will remain the same; however, a discounted rate has been created for the private company presentation fee. More information can be found on our Registration Page.
Company Presentation Resources
For more information about company presentations, please contact firstname.lastname@example.org.